Adage Capital Partners
PRLD icon

Adage Capital Partners’s Prelude Therapeutics PRLD Stock Holding History

Adage Capital Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Buy
+766,095
New +$3.33M 0.01% 828

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Adage Capital Partners's PRLD Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 766,095 shares worth $4.08M. The stake represents 0.01% of the portfolio and ranks #828 among its holdings.

68 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Adage Capital Partners held 766,095 shares of Prelude Therapeutics worth $4.08M as of Q2 2026.
  • Prelude Therapeutics was a new Adage Capital Partners position in Q2 2026.
  • Prelude Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #828 holding.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.